GlaxoSmithKline Pharmaceuticals Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) just released its latest quarterly results and things are looking bullish. It was overall a positive result, with revenues beating expectations by 9.7% to hit ₹12b. GlaxoSmithKline Pharmaceuticals also reported a statutory profit of ₹19.83, which was an impressive 20% above what the analysts had forecast. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Following last week's earnings report, GlaxoSmithKline Pharmaceuticals' four analysts are forecasting 2027 revenues to be ₹42.7b, approximately in line with the last 12 months. Statutory per-share earnings are expected to be ₹68.23, roughly flat on the last 12 months. In the lead-up to this report, the analysts had been modelling revenues of ₹42.6b and earnings per share (EPS) of ₹68.78 in 2027. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
Check out our latest analysis for GlaxoSmithKline Pharmaceuticals
The analysts reconfirmed their price target of ₹3,097, showing that the business is executing well and in line with expectations. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on GlaxoSmithKline Pharmaceuticals, with the most bullish analyst valuing it at ₹3,500 and the most bearish at ₹2,900 per share. This is a very narrow spread of estimates, implying either that GlaxoSmithKline Pharmaceuticals is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The period to the end of 2027 brings more of the same, according to the analysts, with revenue forecast to display 3.4% growth on an annualised basis. That is in line with its 4.1% annual growth over the past five years. Compare this with the broader industry (in aggregate), which analyst estimates suggest will see revenues grow 12% annually. So it's pretty clear that GlaxoSmithKline Pharmaceuticals is expected to grow slower than similar companies in the same industry.
The Bottom Line
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that GlaxoSmithKline Pharmaceuticals' revenue is expected to perform worse than the wider industry. The consensus price target held steady at ₹3,097, with the latest estimates not enough to have an impact on their price targets.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for GlaxoSmithKline Pharmaceuticals going out to 2029, and you can see them free on our platform here..
That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with GlaxoSmithKline Pharmaceuticals , and understanding this should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.